Sunshine Biopharma Stock Probability of Future Stock Price Finishing Over 2.65
| SBFM Stock | USD 2.14 0.17 7.36% |
Sunshine |
Sunshine Biopharma Target Price Odds to finish over 2.65
The tendency of Sunshine Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 2.65 or more in 90 days |
| 2.14 | 90 days | 2.65 | about 67.16 |
Based on a normal probability distribution, the odds of Sunshine Biopharma to move over $ 2.65 or more in 90 days from now is about 67.16 (This Sunshine Biopharma probability density function shows the probability of Sunshine Stock to fall within a particular range of prices over 90 days) . Probability of Sunshine Biopharma price to stay between its current price of $ 2.14 and $ 2.65 at the end of the 90-day period is about 31.85 .
Given the investment horizon of 90 days Sunshine Biopharma has a beta of 0.32. This usually implies as returns on the market go up, Sunshine Biopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Sunshine Biopharma will be expected to be much smaller as well. Additionally Sunshine Biopharma has an alpha of 0.1302, implying that it can generate a 0.13 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Sunshine Biopharma Price Density |
| Price |
Predictive Modules for Sunshine Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sunshine Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sunshine Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Sunshine Biopharma is not an exception. The market had few large corrections towards the Sunshine Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sunshine Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sunshine Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.13 | |
β | Beta against Dow Jones | 0.32 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | 0.03 |
Sunshine Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sunshine Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sunshine Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sunshine Biopharma has a poor financial position based on the latest SEC disclosures |
Sunshine Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sunshine Stock often depends not only on the future outlook of the current and potential Sunshine Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sunshine Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.2 K | |
| Cash And Short Term Investments | 16.3 M |
Sunshine Biopharma Technical Analysis
Sunshine Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Sunshine Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Sunshine Biopharma. In general, you should focus on analyzing Sunshine Stock price patterns and their correlations with different microeconomic environments and drivers.
Sunshine Biopharma Predictive Forecast Models
Sunshine Biopharma's time-series forecasting models is one of many Sunshine Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Sunshine Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Sunshine Biopharma
Checking the ongoing alerts about Sunshine Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Sunshine Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sunshine Biopharma has a poor financial position based on the latest SEC disclosures |
Check out Sunshine Biopharma Backtesting, Sunshine Biopharma Valuation, Sunshine Biopharma Correlation, Sunshine Biopharma Hype Analysis, Sunshine Biopharma Volatility, Sunshine Biopharma History as well as Sunshine Biopharma Performance. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.